LMR Partners’s Neurogene NGNE Stock Holding History

LMR Partners’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-628	Closed	-$8K	–	1214
2022 Q3	$8K	Hold	628	–	–	﹤0.01%	1194
2022 Q2	$13K	Buy	+628	New	+$15.3K	﹤0.01%	1250

Other funds holding NGNE

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

LMR Partners's NGNE Position: Q4 2022 in Review

LMR Partners sold out of Neurogene (NGNE) in Q4 2022, closing a stake of 628 shares — an estimated $8K sold.

LMR Partners first reported a position in NGNE in Q2 2022 and held it in 2 quarters. The position peaked at $13K in Q2 2022. 45 funds tracked by Wall St. Rank hold NGNE as of Q4 2022.

LMR Partners reported no remaining Neurogene position as of Q4 2022 after selling out during the quarter.
LMR Partners sold 628 Neurogene shares in Q4 2022, an estimated $8K.
LMR Partners first reported a position in Neurogene in Q2 2022 and held it in 2 quarters.
LMR Partners's Neurogene position peaked at $13K in Q2 2022.
45 funds tracked by Wall St. Rank held Neurogene as of Q4 2022.

Based on LMR Partners's 13F filing for Q4 2022, filed 14 Feb 2023.